Merck Commences P-III Study of MK-1084 Plus Keytruda as a Treatment of Metastatic Non-Small Cell Lung Cancer
Shots:
- Merck has commenced the P-III clinical evaluation of MK-1084 + Keytruda vs Keytruda + PBO in treatment-naïve KRAS G12C-mutated metastatic NSCLC patients (n=600) having PD-L1 TPS ≥50% with 1EPs as PFS & OS as well as 2EPs include ORR & DoR
- The company is assessing MK-1084 alone and in combinations under the ongoing P-I study for its safety, efficacy, tolerability & PK characteristics for the treatment of advanced solid tumors associated with KRAS G12C mutations. The data was highlighted at the ESMO 2023
- MK-1084 is a potent and specific covalent inhibitor of KRAS G12C, the mutations of which are commonly observed in non-small cell lung cancer, pancreatic, urogenital and colorectal cancers
Ref: Merck | Image: Merck
Related News:- Pfizer’s Braftovi (encorafenib) + Mektovi (binimetinib) Receives the US FDA’s Approval for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
